Highlights
- •No antianginal drug improves survival while they have roughly the same level of evidence on angina relief.
- •A more tailored approach to antianginal treatment may have additional benefits beyond angina relief.
- •Individualizing antianginal drug treatment according the hemodynamic parameters as well as the comorbidities of patients.
Abstract
Stable angina represents a chronic and often debilitating condition that affects daily
activities and quality of life in patients with chronic coronary syndromes (CCS).
Current European Society of Cardiology guidelines recommend a four-step approach for
the medical treatment of patients taking into consideration hemodynamic variables
(heart rate and blood pressure) and the presence or absence of left ventricular dysfunction.
However, CCS patients often have several comorbidities and risk factors. Thus, a tailored
approach that takes into consideration patient risk factors and comorbidities may
have additional benefits beyond angina relief. This is a state of the art review of
stable angina treatment based on the currently available evidence.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Internal MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Reference
- Impact of stable angina on health status and quality of life perception of currently treated patients. The BRIDGE 2 survey.Eur J Intern Med. 2019; 70: 60-67https://doi.org/10.1016/j.ejim.2019.09.013
- American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2020 update: a report from the American Heart Association.Circulation. 2020; 141: e139-e596
- The ESC 2019 CCS guidelines: Have we left our patients and scientific evidence behind?.Eur J Intern Med. 2020; 72: 5-8https://doi.org/10.1016/j.ejim.2019.12.012
- Medical treatment of stable angina: A tailored therapeutic approach.Int J Cardiol. 2016 Oct 1; 220: 445-453https://doi.org/10.1016/j.ijcard.2016.06.150
- Investigators of the Prospective, Noninterventional, Observational Study of the Antianginal Efficacy of Ivabradine During a 4-Month Treatment of a Greek Population With Coronary Artery Disease.Clin Cardiol. 2015; 38: 725-732https://doi.org/10.1002/clc.22479
- ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes.Eur Heart J. 2020; 41: 407-477https://doi.org/10.1093/eurheartj/ehz425
- Puskas JD. Fifty years of coronary artery bypass grafting.J Thorac Dis. 2018; 10: 1960-1967
- Results from coronary angioplasty and implications for the future.American heart journal. 1982; 103 (4 Pt 2): 779-783
Yusuf S, Zucker D, Chalmers TC. Ten-year results of the randomized control trials of coronary artery bypass graft surgery: tabular data compiled by the collaborative effort of the original trial investigators. Part 1 of 2. The Online journal of current clinical trials. 1994;Doc No 145:[3987 words; 38 paragraphs].
- A Comparison of Angioplasty with Medical Therapy in the Treatment of Single-Vessel Coronary Artery Disease.New England Journal of Medicine. 1992; 326: 10-16
- Coronary angioplasty versus medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA-2) trial. RITA-2 trial participants.Lancet. 1997; 350: 461-468
- Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis.Lancet. 2016; 387: 957-967
- Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.CANTOS Trial Group. 2017 Sep 21; 377 (N Engl J Med): 1119-1131https://doi.org/10.1056/NEJMoa1707914
- Renin angiotensin system inhibitors for patients with stable coronary artery disease without heart failure: systematic review and meta-analysis of randomized trials.BMJ. 2017; 356: j4
- Preexisting cardiovascular disease, and risk of major cardiovascular events in patients with type 2 diabetes mellitus: systematic review with meta-analysis of cardiovascular outcome trials and intensive glucose control trials.J Am Heart Assoc. 2019; 8e012356
- Healthy behavior, risk factor control, and survival in the COURAGE Trial.J Am Coll Cardiol. 2018; 72: 2297-2305
- Optimal medical therapy improves clinical outcomes in patients undergoing revascularization with percutaneous coronary intervention or coronary artery bypass grafting: insights from the Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery (SYNTAX) trial at the 5-year follow-up.Circulation. 2015; 131: 1269-1277
- Medical Therapy Utilization and Long-Term Outcomes Following Percutaneous Coronary Intervention: Five-Year Results From the Veterans Affairs Clinical Assessment, Reporting, and Tracking System Program.Circ Cardiovasc Qual Outcomes. 2019; 12e005455
- Optimal Medical Therapy with or without PCI for Stable Coronary Disease.New England Journal of Medicine. 2007; 356: 1503-1516
- A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease.New England Journal of Medicine. 2009; 360: 2503-2515
- Fractional Flow Reserve–Guided PCI versus Medical Therapy in Stable Coronary Disease.New England Journal of Medicine. 2012; 367: 991-1001
- Initial Invasive or Conservative Strategy for Stable Coronary Disease.New England Journal of Medicine. 2020; 382: 1395-1407
- Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.Lancet. 2010 Sep 11; 376: 875-885https://doi.org/10.1016/S0140-6736(10)61198-1
- β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease.JAMA. 2012; 308: 1340-1349
- β-blocker therapy and cardiac events among patients with newly diagnosed coronary heart disease.J Am Coll Cardiol. 2014; 64: 247-252
- β-blockers, calcium antagonists, and mortality in stable coronary artery disease: an international cohort study.Eur Heart J. 2019; 40: 1399-1407
- Clinical outcomes with β-blockers for myocardial infarction: a meta-analysis of randomized trials.Am J Med. 2014; 127: 939-953
- β-Blockers and Mortality After Acute Myocardial Infarction in Patients Without Heart Failure or Ventricular Dysfunction.J Am Coll Cardiol. 2017; 69: 2710-2720
- Beta-blockers after acute myocardial infarction: an old drug in urgent need of new evidence!.Eur Heart J. 2020 Oct 1; 41: 3530-3532https://doi.org/10.1093/eurheartj/ehaa436
- Effects of atenolol, nifedipine SR and their combination on the exercise test and the total ischaemic burden in 608 patients with stable angina. The TIBET Study Group.Eur Heart J. 1996; 17: 96-103
- Comparison of nifedipine gastrointestinal therapeutic system and atenolol on antianginal efficacies and exercise hemodynamic responses in stable angina pectoris.Am J Cardiol. 1994; 73: 23-28
- Long-term beta blockers for stable angina: systematic review and meta-analysis.Eur J Prev Cardiol. 2012; 19: 330-341
- Vasodilator β-blockers: a different class of antihypertensive agents?.Future Cardiol. 2014; 10: 669-671
- Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: A scientific statement from the american heart association.Circulation. 2020; 141: e779-e806
- Nitroglycerine as a remedy for angina pectoris.Lancet. 1879; 1: 80-81
- Ivabradine: I(f) inhibition in the management of stable angina pectoris and other cardiovascular diseases.Drugs Today (Barc). 2008; 44: 171-181
- Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina.Eur Heart J. 2005; 26: 2529-2536
- Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial.Eur Heart J. 2009; 30: 540-548
- Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial.Lancet. 2008; 372: 807-816
- Rationale, design, and baseline characteristics of the Study assessInG the morbidity-mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease (SIGNIFY trial): a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical heart failure.Am Heart J. 2013; 166 (654-661): e656
- Pharmacovigilance Risk Assessment Committee: (PRAC). 2014; (Web site http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Corlentor_and_Procoralan_20/Opinion_provided_by_Committee_for_Medicinal_Products_for_Human_Use/WC500181901.pdf Published November 6, 2014. Updated November 6, 2014. Accessed December 10, 2015)
- Pathophysiology and pharmacology of the cardiac "late sodium current.Pharmacol Ther. 2008; 119: 326-339
- Once Daily Therapy With Isosorbide-5-Mononitrate Causes Endothelial Dysfunction in Humans. Evidence of a Free-Radical–Mediated Mechanism.J Am Coll Cardiol. 2007; 49: 1289-1295
- Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina.J Am Coll Cardiol. 2004; 43: 1375-1382
- Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial.JAMA. 2004; 291: 309-316
- Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial.J Am Coll Cardiol. 2006; 48: 566-575
- Effects of ranolazine in symptomatic patients with stable coronary artery disease. A systematic review and meta-analysis.Int J Cardiol. 2013; 169: 262-270
- Relative efficacy of antianginal drugs used as add-on therapy in patients with stable angina: A systematic review and meta-analysis.Eur J Prev Cardiol. 2015; 22: 837-848
- Effects of ivabradine and ranolazine in patients with microvascular angina pectoris.Am J Cardiol. 2013; 112: 8-13
- Ranolazine reduces angina frequency and severity and improves quality of life: Observational study in patients with chronic angina under ranolazine treatment in Greece (OSCAR-GR).Int J Cardiol. 2016; 205: 111-116
- Ranolazine Reduces Patient-Reported Angina Severity and Frequency and Improves Quality of Life in Selected Patients with Chronic Angina.Drugs R D. 2013; 13: 207-213
- Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial.Circulation. 2007; 116: 1647-1652
- Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial.JAMA. 2007; 297: 1775-1783
- Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial.J Am Coll Cardiol. 2009; 53: 1510-1516
- RIVER-PCI investigators. Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial.Lancet. 2016; 387: 136-145
- Trimetazidine in the Prevention of Tissue Ischemic Conditions.Angiology. 2019; 70 (Apr): 291-298https://doi.org/10.1177/0003319718780551
- Trimetazidine and cardioprotection: facts and perspectives.Angiology. 2015; 66 (Mar): 204-210https://doi.org/10.1177/0003319714530040
- ATPCI investigators. Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomised, double-blind, placebo-controlled trial.Lancet. 2020 Sep 19; 396: 830-838https://doi.org/10.1016/S0140-6736(20)31790-6
IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial.The Lancet 359:1269–1275. doi:10.1016/S0140-6736(02)08265-X.
- Antianginal and anti-ischemic efficacy of nicorandil in comparison with isosorbide-5-mononitrate and isosorbide dinitrate: results from two multicenter,double-blind, randomized studies with stable coronary heart disease patients.J Cardiovasc Pharmacol. 1992; 20 (Suppl): S74-S81
- A double-blind comparison of nicorandil and metoprolol in stable effort angina pectoris.Cardiovasc Drugs Ther. 1993; 7: 119-123
- Attenuation of anti-ischemic efficacy during chronic therapy with nicorandil in patients with stable angina.Am J Cardiol. 1999; 83 (1120–4): A9
- 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.J Am Coll Cardiol. 2012; 60: e44-e164
C:/Users/man/Downloads/11 12 15 Sanofi Nicorandil Alert (1).pdf n.d.
(NICE) NIfHaCE. Stable angina: management. https://www.nice.org.uk/guidance/cg126 (4/2016; date last accessed) 2016.
- Pharmacological and emerging therapies in the treatment of chronic angina.Lancet. 2015; 386: 691-701
- Stable angina in Spain and its impact on quality of life. The AVANCE registry.Rev Esp Cardiol (Engl Ed). 2012; 65: 734-741
- The prevalence of weekly angina among patients with chronic stable angina in primary care practices: The Coronary Artery Disease in General Practice (CADENCE) Study.Arch Intern Med. 2009; 169: 1491-1499
- StaBle Angina: Pe Rcept Ion of Nee Ds, Quality of Life and Mana Gem Ent of Patients (BRIDGE Study)-A Multinational European Physician Survey.Angiology. 2018; 3319718796313
- Practice Guidelines for the management of arterial hypertension of the European Society of Hypertension and the European Society of Cardiology: ESH/ESC Task Force for the Management of Arterial Hypertension.J Hypertens. 2018; 36: 2284-2309
- 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.Eur Heart J. 2016; 37: 2129-2200
- Beta-blocker Use in Moderate and Severe Chronic Obstructive Pulmonary Disease.Med Arch. 2019; 73: 72-75
- Effect of beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study.BMJ. 2011; 342: d2549
- 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology.Eur. Heart J. 2013; 34: 2949-3003
- Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.JAMA. 2004; 292: 2227-2236
- Effects of Carvedilol Compared to Nebivolol on Insulin Resistance and Lipid Profile in Patients With Essential Hypertension.J Cardiovasc Pharmacol Ther. 2017; 22: 65-70
- Antianginal Therapy for Stable Ischemic Heart Disease: A Contemporary Review.J Cardiovasc Pharmacol Ther. 2017; 22: 499-510
- Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina).Journal of the American College of Cardiology. 2013; 61: 2038-2045
- Antihyperglycemic and Metabolic Effects of Ranolazine in Patients With Diabetes Mellitus.Am J Cardiol. 2018; 121: 509-512
- Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy.Am Heart J. 2003; 146: E18
- Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Trimetazidine European Multicenter Study Group.Br J Clin Pharmacol. 1994; 37: 279-288
- Effectiveness and safety of anti-ischemic trimetazidine in patients with stable angina pectoris and Type 2 diabetes.J Comp Eff Res. 2017; 6: 649-657
- Effect of European Medicines Agency's restrictions on trimetazidine utilization in Portugal.Pharmacoepidemiol Drug Saf. 2018; 27: 962-968
- A randomized, placebo-controlled trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction (CMD): impact on angina and myocardial perfusion reserve.Eur. Heart J. 2016; 37: 1504-1513
- Ranolazine in symptomatic diabetic patients without obstructive coronary artery disease: Impact on microvascular and diastolic function.J Am Heart Assoc. 2017 May 4; 6e005027https://doi.org/10.1161/JAHA.116.005027
- Coronary Microvascular Disease Pathogenic Mechanisms and Therapeutic Options: JACC State-of-the-Art Review.J Am Coll Cardiol. 2018; 72: 2625-2641
- Effect of renal impairment on multiple-dose pharmacokinetics of extended-release ranolazine.Clin Pharmacol Ther. 2005; 78: 288-297
Article info
Publication history
Published online: August 18, 2021
Accepted:
August 7,
2021
Received in revised form:
July 24,
2021
Received:
May 27,
2021
Identification
Copyright
© 2021 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
